We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
The Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab (KEYTRUDA, Merck) for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) ...